Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 40150

Original article / research
Table of Contents - Year : 2016 | Month : August | Volume : 10 | Issue : 8 | Page : ZC113 - ZC117

Effect of Alendronate with TCP Bone Substitute in Surgical Therapy of Periodontal Intra-Osseous Defects: A Randomized Controlled Clinical Trial ZC113-ZC117

Rohini Naineni, Vishali Ravi, Dwijendra Kocherlakota Subbaraya, Jammula Surya Prasanna, Veerendranath Reddy Panthula, Rekha Rani Koduganti

Dr. Rohini Naineni,
Reader, Department of Periodontics, Panineeya Mahavidyalaya Institute of Dental Sciences,
Hyderabad, Telangana-500045, India.

Introduction: Alendronate (ALN), an aminobisphosphonate, inhibits osteoclastic bone resorption and also stimulates osteogenesis. Beta-Tricalcium Phosphate (-TCP) is an osteoconductive graft material which provides a scaffold for bone formation and also a widely used drug delivery vehicle for growth factors and antibiotics. Drug delivery vehicles, like -TCP, improve the potency of the drugs by specific local site delivery of the drug, optimal release characteristics and easy handling.

Aim: The aim of the this study was to evaluate the bone formation potential of 400g ALN delivered in -TCP in the treatment of periodontal intra-osseous defects.

Materials and Methods: Thirty patients with periodontal defects were randomly assigned to 400g ALN + -TCP + Saline (test) group and -TCP + Saline (active-control) group. Clinical parameters like Clinical Attachment Level (CAL) gain, Probing Depth (PD) reduction, post-operative Gingival Recession (GR) were assessed from the baseline, 3 months and 6 months recordings. Radiographic parameters like Linear Bone Growth (LBG), Percentage Bone Fill (%BF), and change in alveolar crest height (ACH) were assessed from baseline and 6 months radiographs.

Results: Mean measurements in the ALN test group for CAL gain (3.4 0.74 mm), PD reduction (4.33 0.82 mm), LBG (2.88 0.88 mm), and %BF (51.98 15.84%) were significantly greater with a p-value <0.05 compared to the mean measurements of CAL gain (2.20 0.86 mm), PD reduction (3.20 1.15 mm), LBG (1.70 0.39 mm), and %BF (30.35 6.88%) of the control group. There was mild alveolar crestal apposition (0.32 0.68 mm) in the ALN test group and mild alveolar crestal resorption (-0.24 0.40 mm) in the control group.

Conclusion: 400g ALN combined with -TCP bone graft material was effective in improving soft tissue parameters, inhibiting alveolar crestal resorption and enhancing bone formation, compared to -TCP alone.